Company Filing History:
1 out of 1 
4 out of 832,812 Years Active: 2017-2019
Title: Innovations by Cheng-Hsiu Lin in Diabetes and Hyperlipidemia Treatment
Introduction
Cheng-Hsiu Lin is a notable inventor based in Taichung, Taiwan. He has made significant contributions to the field of medical science, particularly in the treatment of metabolic diseases. With a total of 5 patents to his name, Lin's work focuses on innovative methods for managing diabetes and hyperlipidemia.
Latest Patents
One of Lin's latest patents is titled "Use of dehydroeburicoic acid in the treatment or prevention of diabetes and hyperlipidemia." This invention provides a method for treating type 1 diabetes and hyperlipidemia by utilizing dehydroeburicoic acid. The method aims to decrease blood glucose levels, plasma total cholesterol, and triglycerides while increasing insulin levels. Additionally, it enhances the expression of membrane glucose transporter 4 (GLUT4) in skeletal muscle and phospho-AMPK in both skeletal muscle and liver tissue.
Another significant patent is the "Method for treatment of hyperglycemia and hyperlipidemia." This invention addresses metabolic diseases such as type 2 diabetes and obesity. It involves administering a therapeutically effective amount of antcin K to enhance protein expression ratios and reduce blood leptin levels in subjects.
Career Highlights
Throughout his career, Cheng-Hsiu Lin has worked with various companies, including Chun-Ching Shih. His innovative approaches have garnered attention in the medical community, leading to advancements in treatment methodologies for metabolic disorders.
Collaborations
Lin has collaborated with notable individuals such as Chun-Ching Shih and Yueh-Hsiung Kuo. These partnerships have contributed to the development of his groundbreaking patents and research.
Conclusion
Cheng-Hsiu Lin's contributions to the field of diabetes and hyperlipidemia treatment through his innovative patents highlight his role as a significant inventor. His work continues to influence the medical landscape, offering new hope for individuals affected by these metabolic diseases.